The PET Center Radiochemistry Research has focused on neuroscience imaging with particular attention to the serotonin receptor system. Dr. Mathis, senior chemist and director of the PET neuroscience program, has led these efforts. His long-term collaboration with Dr. Klunk (Department of Psychiatry) has produced a novel agent for in vivo imaging of amyloid deposition in Alzheimer's disease, known as PIB or {N-methyl-[11C]}2-(4'-methylaminophenyl)-6-hydroxybenzothiazole.

Recently [18F]FLT was approved for human use and this will be applied to study tumor proliferation. In addition, about 100 other compounds have been radiolabeled and are available for non-human research including [18F]fallypride (dopamine-D2), [11C]MDL 100907 (serotonin-2A), [11C]DASB (serotonin transporter), [18F]FAU and [11C]acetate (tumor proliferation).